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Abstract  
Word count: 265<250 
Objective: To update the consensus recommendations for reporting of quantitative 
optical coherence tomography (OCT) study results, thus revising the previously 
published Advised Protocol for OCT Study Terminology and Elements (APOSTEL) 
recommendations.  
Methods: To identify studies reporting quantitative OCT results, we performed a 
PubMed search for the terms “quantitative” and “optical coherence tomography” from 
2015 to 2017. Corresponding authors of the identified publications were invited to 
provide feedback on the initial APOSTEL recommendations via online surveys 
following the principle of a modified Delphi method. The results were evaluated and 
discussed by a panel of experts, and changes to the initial recommendations were 
proposed. A final survey was recirculated among the corresponding authors to obtain 
a majority vote on the proposed changes. 
Results: One hundred sixteen authors participated in the surveys, resulting in 15 
suggestions, of which 12 were finally accepted and incorporated into an updated 9-
point-checklist. We harmonized the nomenclature of the outer retinal layers, added 
the exact area of measurement to the description of volume scans; we suggested 
reporting device-specific features. We advised to address potential bias in manual 
segmentation or manual correction of segmentation errors. References to specific 
reporting guidelines and room light conditions were removed. The participants’ 
consensus with the recommendations increased from 80% for the previous 
APOSTEL version to greater than 90%. 
Conclusions: The modified Delphi method resulted in an expert-led guideline 
(evidence class III, GRADE criteria) concerning study protocol, acquisition device, 
acquisition settings, scanning protocol, fundoscopic imaging, post-acquisition data 
selection, post-acquisition analysis, nomenclature and abbreviations, and statistical 
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approach. It will still be essential to update these recommendations to new research 
and practices regularly. 
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Introduction  
Increases in the numbers of quantitative optical coherence tomography (OCT) 
studies have raised the need for consistent and coherent standardized reporting 
recommendations. In 2016, the Advised Protocol for OCT Study Terminology and 
Elements (APOSTEL) recommendations were published to provide a 9-point 
checklist of relevant aspects for reporting quantitative retinal OCT studies1. The 
original APOSTEL recommendations were conceived as expert opinion (level D 
evidence according to the Grading of Recommendations Assessment, Development 
and Evaluation, GRADE, working group criteria, www.gradeworkinggroup.org) from 
discussions among the authors, the IMSVISUAL consortium (www.imsvisual.org), 
and consideration of the literature2. Without a formal consensus-building approach, 
and without involving a broader audience, further validation was warranted. We 
aimed to revise and achieve consensus on these recommendations by using a 
modified DELPHI method, including a larger group of OCT scientists and clinicians, 
in a formal procedure to review the consensus and develop level C evidence-based 
guidelines (GRADE criteria)3. The long-term goal was to improve the reproducibility 
and inter-operability of OCT studies for retinal and neuro-ophthalmology diseases.  
 
Methods  
In order to identify experts in the field while minimizing the risk of selection bias, we 
chose to contact corresponding authors of studies reporting quantitative retinal OCT 
results published within 24 months prior to our initial survey by email. Eight hundred 
ninety-two authors (892) of 1189 publications were identified by a PubMed search 
(performed 3 July 2017) using the search terms quantitative and optical coherence 
tomography for 2015 to 2017. The DELPHI method is a systematic, multi-stage 
survey to obtain consensus on a specified question. The process involves multiple 
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rounds of questionnaires presented to participants. The responses are analyzed by a 
panel of experts and fed back to participants and assessed for consensus4. Most of 
the members of the panel of experts were also corresponding authors of quantitative 
retinal OCT studies and were therefore also invited to participate in the survey. 
Following the consensus-building procedure of a modified DELPHI method (Figure 
1), we conducted the following steps: 
1) We contacted all corresponding authors of the identified publications and 
asked them to evaluate and give feedback on the initial APOSTEL 
recommendations. The participants were asked about their agreement on 
each item of the recommendations, rating from 1-full disagreement to 4-full 
approval. Participants were given the opportunity to provide comments. In a 
blinded fashion, we collected feedback and suggestions using a free online 
survey via Google Forms (Initial questionnaire, raw data of survey results can 
be obtained from the corresponding author upon qualified request).  
2) We then formed a panel of 54 international experts who gathered at congress 
meetings and during four rounds of telephone conferences. The aggregated 
results of the initial questionnaire were reviewed online through a second 
questionnaire by the panel, who also revised the original APOSTEL 
recommendations and proposed a list of changes. 
3) This list was then reviewed in a second DELPHI round by the original group of 
corresponding authors through a third online questionnaire (Google Forms). In 
this last DELPHI round, the participants were given the opportunity to approve 
or reject the final list of suggestions of the panel of experts by majority vote. 
Results 
Initial questionnaire: survey about the initial APOSTEL recommendations among 
corresponding authors 
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Seventy-three (8%) of the 892 contacted corresponding authors of quantitative OCT 
studies completed the first online questionnaire and provided feedback, the majority 
of these being ophthalmologists (71%), followed by neurologists (10%), and neuro-
ophthalmologists (10%). Eighty percent of participants agreed with the 
recommendations as they were published, and 95% planned to adhere to the 
recommendations in future publications. At the same time, 64% stated having 
reported their previous research with less detail than suggested.  
 
Second questionnaire: Consensus building with the panel of experts 
Based on the feedback obtained during the first survey, the panel of 54 experts 
drafted a list of 15 suggested changes to the original APOSTEL recommendations. 
Twelve (80%) of these suggestions (see below) were accepted through the second 
questionnaire, while proposals already covered in the original recommendations or to 
include OCT angiography (OCT-A) were rejected. With this feedback, we generated 
a revised version of the APOSTEL recommendations with an updated 9-point 
checklist.  
 
Third questionnaire: second DELPHI round with corresponding authors. 
One hundred sixteen (13%) of the 892 corresponding authors responded to the third 
survey. Among them, 53% were ophthalmologists, 35% neurologists, and 12% were 
non-MD researchers. The overall acceptance of the proposed changes was above 
95%, with the only exception of the recommendation to report the pixel to mm ratio 
and the image format if the images are exported from the device for analysis, which 
was accepted by 84% of the authors.  
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Summary of revisions 
After the modified DELPHI process for consensus building, we decided to maintain 
the initial recommendations of stating the acquisition protocol, imaging modalities 
and addressing concomitant eye pathologies with the exact scanning protocol. The 
following changes made to the original APOSTEL recommendations checklist are 
printed in bold in Table 1 and summarized below: 
1) As already addressed in correspondence to the initial recommendations5, we 
harmonized the nomenclature of the outer retinal layers to match the 
consensus paper by Staurenghi et al 2014 (Figure 2)6.  
2) We removed references to specific reporting guidelines to avoid favoring any 
guidelines or omitting relevant recommendations.  
3) When utilized, we suggest reporting device-specific features (e.g. enhanced 
depth imaging, swept-source OCT, adaptive optics).  
4) We added the exact area of measurement (e.g. analysis grids) to the 
description of volume scans. 
5) We also added a commentary regarding the importance of addressing 
potential bias in manual segmentation or manual correction of segmentation 
errors (masking). In several comments, concerns were raised regarding the 
length of the methodology section of articles that fully adhered to the 
APOSTEL recommendations. In case of limited word count availability, we 
now advise submitting the exact OCT methodology as supplementary 
material, if permitted. 
6) Another issue raised by several comments was that the relevance of some of 
the details to be reported regarding the acquisition setting, namely the room 
lighting conditions and if pupils were dilated. The panel of experts agreed that 
reporting the ambient lighting condition is likely to be of low clinical 
importance, although shaded room lighting is suggested. However, off-axis 
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beam placement could affect the results of OCT imaging studies, and the risk 
for this phenomenon increases with pupil dilation and is greater for the outer 
retinal layers (OPL/ONL) compared to the inner retinal layers (pRNFL to 
INL)7.Oberwahrenbrook and colleagues showed that the greatest error is for 
the outer retinal layers8. Therefore, pupil dilation is relevant since it can 
directly affect quantitative OCT measures. We, thus, omitted room light 
conditions but retained pupil dilation.  
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Discussion 
The formal consensus-building approach of a modified DELPHI method was used 
to revise the APOSTEL recommendations for the reporting of quantitative OCT 
studies.  
We observed a high consensus of the participants already with the initial APOSTEL 
recommendations in the first survey. The vast majority of the participants 
acknowledged the need for guidance.  
While the original APOSTEL recommendations were conceived by a panel 
dominated by neurologists, a more heterogeneous mix of specialties, with broader 
expertise, contributed to this new version, the majority being ophthalmologists. 
Ninety-seven percent of all participants agreed that that the APOSTEL 2.0 
guidelines should apply to all studies reporting on quantitative retinal OCT research 
and not be restrained to certain disorders or disciplines. Furthermore, we believe 
that choosing to identify the experts to be addressed by the survey as the 
corresponding authors of relevant research articles based on a PubMed search 
assured a broad consensus-building approach, eliminating the selection bias 
typically immanent to expert consortia. However, there was a low response rate9: 
eight percent of the contacted corresponding authors responded to the first round 
of the survey and 13% to the second round. Possible explanations for this limitation 
may include the fact that corresponding authors are senior supervisors or principal 
investigators and are not necessarily as involved in the technical details and 
specifications addressed by the APOSTEL recommendations. Likewise, there are 
time constraints to consider. This can be viewed as a limitation of the study but we 
have to assume that those who participated in the survey were knowledgeable 
about the matter and contact details for the first authors or technicians involved in 
these studies were not available.  
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It has to be acknowledged that the modified Delphi-method tends to eliminate 
extreme (but possibly relevant) positions and steers a middle-course consensus. 
However, all survey participants were given the opportunity to provide feedback in 
free text and all comments were critically discussed among the panel of experts. 
The achieved consensus is based on the opinion of the participants and the panel 
of experts and therefore it should be regularly counterchecked and revised along 
with evolving scientific evidence. 
These recommendations do not cover all aspects and techniques possibly 
amenable to OCT research and are based on expert opinion and a single 
consensus finding investigation rather than on a systematic review of a large body 
of literature. Therefore, they are not intended as an indispensable premise for all 
experimental OCT research. The APOSTEL recommendations are intended for 
clinical OCT studies using established techniques and help to provide the 
necessary comparability between studies.  
Some additions suggested during the revision process were not included in the 
final version as consensus was not reached. One of these suggestions was to 
incorporate a section on OCT-A. We believe the inclusion of details pertaining to 
OCT-A to the APOSTEL 2.0 recommendations would be presently premature. 
The field of OCT-A, both clinically and academically, is in a phase of rapid 
evolution and essentially in its infancy. Its use is not well established in routine 
clinical care, in either the fields of ophthalmology or neurology. Interpretation of 
OCT-A scans across devices is challenging and standardized quantitative OCT-A 
metrics are either lacking and/or vary across OCT platforms. Moreover, there is a 
lack of consensus regarding quality control criteria for image acquisition, and the 
implementation of such standards as it pertains to OCT-A. We acknowledge that 
these limitations are likely to change in the future. For these reasons, we believe 
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the evidence and corresponding investigative and clinical recommendations for 
OCT and OCT-A should remain on separate tracks.  
A future revision of the APOSTEL criteria very likely will also need to consider the 
role of Artificial Intelligence based data from image analyses10. 
In summary, we present revised APOSTEL recommendations based on this 
investigation using a modified DELPHI process that involves a broad group of 
experts. Therefore, the resulting APOSTEL 2.0 can be considered an expert-led 
guideline (evidence class C, GRADE criteria) covering all relevant aspects of 
quantitative retinal OCT research. It will be necessary to update these 
recommendations to new research and practices regularly. 
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1 Study protocol 
 
(a) Describe how many OCT operating sites and graders were included 
(b) Report the timing of OCT compared to other measurements (same day, 
delayed) 
(c) Describe the inclusion and exclusion criteria 
(d) In case of limited word count consider submitting the exact methodology as 
supplementary material 
2 Acquisition device 
 
For all OCT devices used, report data on: 
(a) Manufacturer 
(b) Model  
(c) Version 
(d) Software Version 
(e) Device type (time/spectral domain, swept source, adaptive optics) 
3 Acquisition Settings  
 
Clearly describe the settings in which OCT scans were obtained: 
(a) Pupils dilated before exam(y/n) 
(b) Number of operators and devices* 
 
4 Scanning protocol 
 
Clearly describe the scanning protocol, including: 
(a) Type of scan (circular, volume, star, line, other) 
(b) Location (area of interest, macula, optic nerve head, papillomacular bundle, 
other?) 
(c) Scan parameters (with or without eye tracking) 
- Volume scan: size of scan, area and location of measurement (degrees or 
millimeters), number of B-scans, alignment of B-scans, number of A-scans per B-
scan 
- Radial scan: size of scan area (degrees or mm), number of B-scans, 
alignment of B-scans, number of A-scans per B-scan 
- Ring scan: diameter, A-scans/B-scan, manual or automatic placement of 
ring or method of centering, depth resolution. 
- Line scan: angle, location, number of A-scans, depth resolution. 
5 Fundoscopic imaging (a) Report other imaging modalities used in addition to OCT (fundoscopy, CSLO, 
retinal angiography, autofluorescence imaging, etc.) 
(b) Describe acquisition protocol, including: 
1. Excitation wavelength 
2. Filter sets 
3. Number of frames averaged (if applicable) 
4. Report device specific features when utilized (e.g. enhanced depth imaging, 
swept source OCT, adaptive optics) 
6 Post-acquisition data Describe image selection process including: 
(a) Quality control criteria  
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selection (b) Post-acquisition discard (number and criteria) 




Describe all post-acquisition steps: 
(a) Software used for processing scans and segmentation (may be different 
from acquisition software) 
(b) Which individual retinal layers were segmented/included 
(c) Method of segmentation (automated, semi-automated or manually) 
(d) How potential bias was addressed in the case of manual segmentation or 
manual correction of automated segmentation errors (masking) 
(e) Grid used for data-extraction (size, shape, selected sections) 
(f) Pixel to mm ratio if images are exported (caliper need) 
 
8 Nomenclature and 
abbreviations 
Define: 
(a) Anatomical structures analyzed 
(b) Units of provided measurements (e.g. volume or thickness) 
(c) Report the number of eyes presenting additional retinal pathology. 
Describe qualitative retinal changes and report exact methodology of 
quantification 
9 Statistical approach  Describe: 
(a) Statistical models used for the analyses of OCT data 
(b) Whether data was analyzed by eye or by patient  
*Room light conditions were removed. 
Table 1: 9-point APOSTEL checklist (adapted from (Cruz-Herranz et al., 2016)) 
Above is the modified APOSTEL checklist containing nine important items when 
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Figure 1: The modified DELPHI method 
 
The modified DELPHI method is described as a consensus-building process. 
We contacted 892 authors of quantitative OCT studies identified by pubmed (I) using 
an online survey, in which a feedback on the original APOSTEL 2016 criteria was 
requested. The feedback of the 72 responding OCT authors was analyzed by a 
panel of experts (II), and changes of the APOSTEL recommendations were 
proposed (III). A revised version (IV) was proposed to the OCT authors (n=116), who 
approved the revisions by majority vote, which lead to the final revised 2020 
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Figure 2: The consensus nomenclature for retinal structures  
The different layers (and their boundaries) are illustrated in a central horizontal 
spectral domain OCT scan through the middle of the fovea. Abbreviations of retinal 
structures and layers: ILM (Inner limiting membrane), RNFL (Retinal nerve fiber 
layer), GCL (Ganglion cell layer), IPL (Inner plexiform layer), INL (Inner nuclear 
layer), OPL (Outer plexiform layer), ONL (Outer nuclear layer), ELM (External 
limiting membrane), MZ (Myoid Zone), EZ (Ellipsoid Zone; Inner and Outer segment 
Junction), OSP (Outer segment of the photoreceptors), IZ (Interdigitation zone), RPE 
(Retinal pigment epithelium), BM (Bruch’s Membrane). Compound layers are 
Ganglion cell and inner plexiform layer (GCIP, composite of macular GCL and IPL), 
Inner retinal layers (IRL, composite of macular RNFL, GCL and IPL), and Outer 
nuclear and plexiform layer (ONPL, composite of ONL and OPL). Copyright by 
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